Angiotensin-receptor blockers and risk of alzheimer's disease in hypertension population - A nationwide cohort study

Chien Yi Hsu, Chin Chou Huang, Wan Leong Chan, Po Hsun Huang, Chia Hung Chiang, Tzeng Ji Chen, Chia Min Chung, Shing Jong Lin, Jaw Wen Chen, Hsin Bang Leu

研究成果: 雜誌貢獻文章同行評審

35 引文 斯高帕斯(Scopus)


Background: Although emerging evidence shows angiotensin-receptor blockers (ARBs) may have a beneficial effect against Alzheimer's disease (AD), the association is not consistent. We investigated the association between ARB use and the risk of development of AD using a nationwide, population-based cohort database in Taiwan. Methods and Results: In total, 16,426 newly diagnosed hypertensive patients who were administered ARB without a previous diagnosis of AD were identified from the Taiwan National Health Insurance database. The comparison group consisted of hypertensive patients who did not receive ARB, and were matched to exposed individuals using propensity score by enrolled time, age, sex, and comorbidities. During an average of 5.24±2.01 years of follow-up, a total of 1,031 cases (3.13%) of new AD occurred. The log-rank test showed no significant difference in the AD occurrence rate between subjects exposed to ARBs and non-exposed controls [488 (2.97%) vs. 543 (3.29%), P=0.221]. After adjusting for age, sex, comorbidities, and medications, only advanced age [hazard ratio (HR) 1.12, 95% confidence interval (CI) 1.12-1.13, P<0.001), female sex (HR 1.18, 95% CI 1.04-1.33, P=0.011), diabetes (HR 1.53, 95% CI 1.31-1.79, P<0.001), but not ARB (HR 1.08, 95% CI 0.96-1.22, P=0.222) were independently associated with AD development. Conclusions: The use of ARB was not significantly associated with a reduction of risk of AD in Asian patients with essential hypertension.

頁(從 - 到)405-410
期刊Circulation Journal
出版狀態已發佈 - 2月 4 2013

ASJC Scopus subject areas

  • 心臟病學與心血管醫學


深入研究「Angiotensin-receptor blockers and risk of alzheimer's disease in hypertension population - A nationwide cohort study」主題。共同形成了獨特的指紋。